Advertisement
PTN Notícias Sobre o Forex
Palatin Technologies Completes Sale Of Vyleesi To Cosette Pharma For Up To $171 Mln
Biopharmaceutical company Palatin Technologies, Inc. (PTN) announced Wednesday the sale of Vyleesi to US-based speciality pharmaceutical company Cosette Pharmaceuticals for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million.
RTTNews
|
518 dias atrás
Palatin Technologies Says USPTO Issues Patent On Vyleesi For Hypoactive Sexual Desire Disorder
Biopharmaceutical company Palatin Technologies, Inc. (PTN) announced Tuesday that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled "Use of Bremelanotide in Patients with Controlled Hypertension."
RTTNews
|
813 dias atrás
